08.21.2023
Stay up to date with the latest Mycovia news, press releases, and more. If you have any questions or comments regarding media inquiries, please reach out to mediarelations@mycovia.com.
08.25.2022
Mycovia Pharmaceuticals’ Phase 3 ultraVIOLET Study Evaluating the Efficacy and Safety of VIVJOA™ (oteseconazole) in Women with Recurrent Vulvovaginal Candidiasis (RVVC) Published in the American Journal of Obstetrics and Gynecology
08.02.2022
Mycovia Pharmaceuticals Announces Presentation of Topline Results from Two Studies Evaluating VIVJOA™ (oteseconazole) Capsules in Patients with Recurrent Vulvovaginal Candidiasis (RVVC) at the 2022 IDSOG Annual Meeting
07.26.2022
Mycovia Pharmaceuticals Announces Publication of Positive Phase 3 Data Evaluating VIVJOA™ (oteseconazole) Capsules in Patients with Recurrent Vulvovaginal Candidiasis (RVVC) in NEJM Evidence
07.18.2022